A Case of Graves' Disease Following Vaccination with the Oxford-AstraZeneca SARS-CoV-2 Vaccine: Case Report and Review of the Literature.
AstraZeneca
COVID-19
Graves’ disease
Journal
European journal of case reports in internal medicine
ISSN: 2284-2594
Titre abrégé: Eur J Case Rep Intern Med
Pays: Italy
ID NLM: 101648453
Informations de publication
Date de publication:
2022
2022
Historique:
received:
24
02
2022
accepted:
02
03
2022
entrez:
6
5
2022
pubmed:
7
5
2022
medline:
7
5
2022
Statut:
epublish
Résumé
A 57-year-old man presented to the outpatient clinic with tremor, palpitations, weight loss and fatigue 1 week after receiving the first dose of the Oxford-AstraZeneca SARS-CoV-2 vaccine (ChAdOx1 nCoV-19). Laboratory studies showed a suppressed TSH with elevated total and free T4. Thyroid peroxidase and thyroglobulin antibodies were elevated but thyrotropin receptor autoantibodies were indeterminate. Thyroid scintigraphy with technetium Tc-99m pertechnetate revealed increased diffuse, symmetric uptake. The patient was treated with thiamazole 15 mg three times a day and propranolol with resolution of his symptoms and normalization of his thyroid function tests until discontinuation of the antithyroid drug 6 months after symptom onset. Thyroid autoimmunity triggered by SARS-CoV-2 vaccines is being increasingly recognized among patients with and without a history of autoimmune thyroid disease.Symptoms and signs of thyrotoxicosis, including fever and tachycardia, can be wrongly attributed to the systemic adverse events of these vaccines.Early recognition of this condition is mandatory to allow proper treatment with anti-thyroid medications and radioactive iodine when necessary.
Identifiants
pubmed: 35520363
doi: 10.12890/2022_003275
pii: 3275-1-28348-1-10-20220413
pmc: PMC9067422
doi:
Types de publication
Journal Article
Langues
eng
Pagination
003275Informations de copyright
© EFIM 2022.
Déclaration de conflit d'intérêts
Conflicts of Interests: The Authors declare that there are no competing interest
Références
J Endocrinol Invest. 2022 Jan;45(1):227-228
pubmed: 34342859
J Endocrinol Invest. 2022 May;45(5):1071-1077
pubmed: 35015288
Endocrine. 2021 Dec;74(3):473-474
pubmed: 34648112
J Autoimmun. 2021 Dec;125:102738
pubmed: 34653776
J Clin Transl Endocrinol Case Rep. 2022 Mar;23:100104
pubmed: 34934633
J Investig Med High Impact Case Rep. 2021 Jan-Dec;9:23247096211063356
pubmed: 34939881
Ophthalmic Plast Reconstr Surg. 2021 Nov-Dec 01;37(6):e221-e223
pubmed: 34570048
Immunology. 2022 Apr;165(4):386-401
pubmed: 34957554
Endocrine. 2021 Nov;74(2):226-227
pubmed: 34533769
J Endocrinol Invest. 2022 Apr;45(4):875-882
pubmed: 34792795
Eur J Case Rep Intern Med. 2021 Sep 02;8(9):002807
pubmed: 34671577
Front Immunol. 2021 Jan 19;11:617089
pubmed: 33584709
BMJ Case Rep. 2021 Dec 30;14(12):
pubmed: 34969799
Nat Rev Immunol. 2021 Apr;21(4):195-197
pubmed: 33674759
Front Public Health. 2021 Nov 23;9:778964
pubmed: 34888290
Curr Opin Rheumatol. 2021 Mar 1;33(2):155-162
pubmed: 33332890
Thyroid. 2021 Sep;31(9):1436-1439
pubmed: 33858208